Clinical trials: Cancer of Kidney
Renal Cell Carcinoma
Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC
Metastatic renal cell carcinoma (mRCC) is the most common malignant tumour of the kidneys. Targeted therapies, which were recently introduced in the treatment of mRCC, have become the standard treatment in these patients.
- Trial name
- NCT02315755
- Where
- 19 sites in Turkey (Türkiye)
- Volunteers
- 102 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
To assess the safety and efficacy of SU011248 in patients with metastatic, refractory renal cell carcinoma
- Trial name
- NCT00077974
- Testing
- SU011248
- Where
- 15 sites in United States
- Volunteers
- 106 people
- Sponsor
- Pfizer
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
This is a study that will test how an experimental drug (enfortumab vedotin) affects patients with cancer of the urinary system (urothelial cancer).
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms
- Trial name
- EV-201 (NCT03219333)
- Testing
- Enfortumab vedotin
- Where
- 81 sites in United States, France and 6 more
- Volunteers
- 219 people
- Sponsor
- Astellas Pharma Inc
Multiple Myeloma
An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function
The purpose of this study is to evaluate the effectiveness and safety of bortezomib in participants previously treated for multiple myeloma (cancer of plasma cells in bone marrow causing numerous tumors and characterized by the…
- Trial name
- NCT00718640
- Testing
- Dexamethasone, Bortezomib
- Where
- 5 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Janssen-Ortho Inc., Canada
Melanoma, Renal Cell Carcinoma
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1 experienced patients with untreated brain metastases: 1) melanoma and 2) renal cell carcinoma (RCC).
- Conditions
- Melanoma, Renal Cell Carcinoma, Brain Metastases, PD1/PD-L1 Experienced
- Trial name
- NCT04955743
- Testing
- Pembrolizumab, Lenvatinib
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Yale University
Kidney Cancer
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- S0931 (NCT01120249)
- Testing
- everolimus
- Where
- 1,003 sites in United States, Puerto Rico
- Volunteers
- 1,545 people
- Sponsor
- SWOG Cancer Research Network
Renal Cell Cancer
Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
The purpose of this study is to determine whether an increase in the dose of sorafenib when given over five instead of 7 days/week, will result in an improvement of the response rate (degree of shrinkage of your cancer) and an…
- Trial name
- NCT01189370
- Testing
- sorafenib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Kansas Medical Center
Carcinoma, Renal Cell
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Research Questions: To understand the clinical outcomes of patients treated with sunitinib in first line and axitinib in second line in a real world setting as therapies for metastatic and/or advanced renal cell carcinoma (mRCC).
- Trial name
- NCT04033991
- Testing
- Sunitinib, Axitinib
- Where
- United Kingdom
- Volunteers
- 684 people
- Sponsor
- Pfizer
FSGS, MCD
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Adalimumab, a treatment which blocks tumor necrosis factor (TNF), was tested to see if it changed levels of urine biomarker levels, tissue inhibitor of metalloprotease-1 (TIMP1), and monocyte chemoattractant protein-1 (MCP1).
- Conditions
- FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT04009668
- Testing
- adalimumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Bladder Cancer, Cervical Cancer
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
RATIONALE: Stop-smoking plans, including counseling and nicotine replacement therapy, may help smokers quit smoking. It is not yet known whether counseling and the nicotine lozenge is more effective than counseling and the…
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00365508
- Testing
- nicotine lozenge, nicotine patch
- Where
- 10 sites in United States
- Volunteers
- 642 people
- Sponsor
- Fox Chase Cancer Center
Kidney Cancer
Vaccine Treatment of Kidney Cancer
This study will evaluate the safety and side effects of two experimental vaccines in patients with kidney cancer and determine whether the vaccines "turn on" an immune response to the cancer.
- Trial name
- NCT00089778
- Testing
- 117-126:Fibroblast growth factor 5 (FGF-5), Fibroblast growth factor 5 (FGF-5):172-176/217-220, IL-2
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, Malignant Melanoma
Phase Ib of L-NMMA and Pembrolizumab
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT03236935
- Testing
- L-NMMA, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Advanced Solid Tumors
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors.
- Trial name
- NCT02460224
- Testing
- LAG525, PDR001
- Where
- 24 sites in United States, Australia and 10 more
- Volunteers
- 490 people
- Sponsor
- Novartis Pharmaceuticals
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epithelioid Sarcoma (ES)
- Trial name
- TRuST (NCT02875548)
- Testing
- Tazemetostat
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 58 people
- Sponsor
- Epizyme, Inc.
Advanced Cancers, Sarcoma
Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor
The goal of this clinical research study is to learn if heated intra-abdominal cisplatin can help to control abdominal tumors in patients having surgery to remove the tumors. The safety of this drug will also be studied.
- Trial name
- NCT01277744
- Testing
- Hyperthermic Peritoneal Perfusion (HIPEC), Cisplatin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
This phase Ib/II trial studies the side effects and best dose of plinabulin in combination with radiation therapy and immunotherapy in patients with select cancers that have spread to other places in the body (advanced) after…
- Conditions
- Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT04902040
- Testing
- Atezolizumab, Avelumab, Durvalumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Neoplasms
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.
- Trial name
- NCT00678392
- Testing
- Axitinib (AG-013736), Sorafenib
- Where
- 294 sites in United States, Australia and 20 more
- Volunteers
- 723 people
- Sponsor
- Pfizer
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Renal Cell Carcinoma
Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
Multi-Center Randomized Open-Label Study of single agent IMO-2055 Patients who have Metastatic or Locally Recurrent Clear Cell Renal Carcinoma (RCC)
- Trial name
- NCT00729053
- Testing
- IMO-2055
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Solid Tumors, High Grade Gliomas
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
Study aimed to assess the reproducibility of PET imaging using AH111585 (18F) Injection. Subjects are evaluable if they undergo 2 administrations of AH111585 (18F) Injection (3 to 8 days apart) and the corresponding PET…
- Conditions
- Solid Tumors, High Grade Gliomas, Lung Cancer, Head and Neck Cancer
- Trial name
- NCT00918281
- Testing
- Fluciclatide Injection
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- GE Healthcare